Alvotech (ALVO) Asset Writedowns and Impairment (2021 - 2026)
Alvotech's (ALVO) quarterly Asset Writedowns and Impairment came in at $3.1 million in Q1 2026, up 345.63% YoY from $686000.0 in Q1 2025, and up 135.09% on a QoQ basis from -$8.7 million in Q4 2025.
Alvotech (ALVO) Asset Writedowns and Impairment (2021 - 2026) Analysis & Trends
Alvotech (ALVO) has 5 years of Asset Writedowns and Impairment data on file, last reported at $3.1 million in Q1 2026.
- Quarterly Asset Writedowns and Impairment rose 345.63% year-over-year to $3.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.4 million (up 349.84% YoY) and the FY2023 annual result came in at $21.5 million, changed N/A from the prior year.
- Asset Writedowns and Impairment rose to $3.1 million in Q1 2026, from -$8.7 million in the prior quarter.
- In the past five years, Asset Writedowns and Impairment ranged from a high of $27.3 million in Q4 2022 to a low of -$8.7 million in Q4 2025.
- A 4-year average of $2.2 million and a median of $686000.0 in 2025 frame the typical range for Asset Writedowns and Impairment.
- Annual changes were most pronounced in 2022 — Asset Writedowns and Impairment soared 43450.79% — and 2025, when it slumped 150.16%.
- Tracing ALVO's Asset Writedowns and Impairment over 4 years: stood at $27.3 million in 2022, then sank by 112.75% to -$3.5 million in 2024, then tumbled by 150.16% to -$8.7 million in 2025, then jumped by 135.09% to $3.1 million in 2026.
- The last three Asset Writedowns and Impairment figures came in at $3.1 million (Q1 2026), -$8.7 million (Q4 2025), and $3.5 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 44.51 Bn | 43.55 Bn | - |
| 2 | Teva Pharmaceutical Industries | 43.52 Bn | 39.86 Bn | 2.15 Bn |
| 3 | Zoetis | 32.43 Bn | 30.75 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn |
| 5 | United Therapeutics | 21.87 Bn | 19.21 Bn | 683.80 Mn |
| 6 | Viatris | 18.98 Bn | 18.09 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.43 Bn | 15.04 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 12.02 Bn | 11.49 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - |
| 10 | Alvotech | 1.30 Bn | 1.30 Bn | 5.09 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 3.06 Mn |
| Mar 31, 2026 | 3.06 Mn |
| Dec 31, 2025 | -8.71 Mn |
| Dec 31, 2025 | -8.71 Mn |
| Sep 30, 2025 | 3.48 Mn |
| Sep 30, 2025 | 3.48 Mn |
| Jun 30, 2025 | 4.55 Mn |
| Jun 30, 2025 | 4.55 Mn |
| Mar 31, 2025 | 686,000.00 |
| Mar 31, 2025 | 686,000.00 |
| Dec 31, 2024 | -3.48 Mn |
| Dec 31, 2024 | -3.48 Mn |
| Sep 30, 2024 | 3.41 Mn |
| Sep 30, 2024 | 3.41 Mn |
| Jun 30, 2024 | -1.56 Mn |
| Jun 30, 2024 | -1.56 Mn |
| Mar 31, 2024 | -5.38 Mn |
| Mar 31, 2024 | -5.38 Mn |
| Dec 31, 2022 | 27.31 Mn |
| Dec 31, 2022 | 27.31 Mn |